Title: HOUSE BILL 37
Official Title: HOUSE BILL 37
Number of Sections: 3
Source: versions - Current Version
Media Type: application/pdf
Strikethrough Detection: 2 sections found

================================================================================

Section 1:
By Davis
SENATE BILL 428
By Reeves
AN ACT to amend Tennessee Code Annotated, Title 8;
Title 53; Title 56; Title 63; Title 68 and Title 71,
relative to the use of drugs for the treatment of
pain.
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE:

Section 2:
SECTION 1. Tennessee Code Annotated, Title 56, Chapter 7, is amended by adding
the following new part:
56-7-3801.
As used in this part:
(1) "Group insurance plan" means a group insurance plan that covers
state employees approved pursuant to title 8, chapter 27;
(2) "Healthcare prescriber" means a prescriber as defined in ยง 53-10-
203;
(3) "Insurer" means an insurer that offers a group insurance plan; and
(4) "Non-opioid treatment" means a drug or biological product that is
indicated to produce analgesia without acting on the body's opioid receptors.
56-7-3802.
(a) Except as otherwise provided in this section, an insurer, for purposes of
offering a group insurance plan, may adopt or amend a state preferred drug list (PDL).
(b)
(1) In establishing and maintaining the PDL, the insurer shall ensure that
a non-opioid drug approved by the United States food and drug administration for
the treatment or management of pain is not disadvantaged or discouraged with
SB0428
000599
- 1 -
respect to coverage relative to an opioid or narcotic drug for the treatment or
management of pain on the PDL.
(2) Subdivision (b)(1) does not prohibit an opioid medication from being
preferred over other opioid medications, or a non-opioid medication from being
preferred over other non-opioid medications.
(c) This section applies to a non-opioid drug immediately upon its approval by
the United States food and drug administration for the treatment or management of pain,
regardless of whether the drug has been reviewed by the insurer for inclusion on the
PDL. This section also applies to drugs being provided under a contract between the
insurer and a pharmacy benefits manager for purposes of a group insurance plan.
56-7-3803.
(a) An insurer, for purposes of offering a group insurance plan, shall ensure that
reimbursement is provided to a healthcare prescriber who provides a non-opioid
treatment to a covered employee under the group insurance plan.
(b) The insurer shall ensure that, to the extent permitted by law, a hospital that
provides either inpatient or outpatient services to a recipient is reimbursed separately
under the group insurance plan for any non-opioid treatment provided as a part of those
services.

Section 3:
SECTION 2. This act takes effect July 1, 2025, the public welfare requiring it.
- 2 - 000599
[DELETED: S5A5(]
[DELETED:  -0((5((S]


================================================================================

Raw Text:
HOUSE BILL 37
By Davis
SENATE BILL 428
By Reeves
AN ACT to amend Tennessee Code Annotated, Title 8;
Title 53; Title 56; Title 63; Title 68 and Title 71,
relative to the use of drugs for the treatment of
pain.
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE:
SECTION 1. Tennessee Code Annotated, Title 56, Chapter 7, is amended by adding
the following new part:
56-7-3801.
As used in this part:
(1) "Group insurance plan" means a group insurance plan that covers
state employees approved pursuant to title 8, chapter 27;
(2) "Healthcare prescriber" means a prescriber as defined in ยง 53-10-
203;
(3) "Insurer" means an insurer that offers a group insurance plan; and
(4) "Non-opioid treatment" means a drug or biological product that is
indicated to produce analgesia without acting on the body's opioid receptors.
56-7-3802.
(a) Except as otherwise provided in this section, an insurer, for purposes of
offering a group insurance plan, may adopt or amend a state preferred drug list (PDL).
(b)
(1) In establishing and maintaining the PDL, the insurer shall ensure that
a non-opioid drug approved by the United States food and drug administration for
the treatment or management of pain is not disadvantaged or discouraged with
SB0428
000599
- 1 -

respect to coverage relative to an opioid or narcotic drug for the treatment or
management of pain on the PDL.
(2) Subdivision (b)(1) does not prohibit an opioid medication from being
preferred over other opioid medications, or a non-opioid medication from being
preferred over other non-opioid medications.
(c) This section applies to a non-opioid drug immediately upon its approval by
the United States food and drug administration for the treatment or management of pain,
regardless of whether the drug has been reviewed by the insurer for inclusion on the
PDL. This section also applies to drugs being provided under a contract between the
insurer and a pharmacy benefits manager for purposes of a group insurance plan.
56-7-3803.
(a) An insurer, for purposes of offering a group insurance plan, shall ensure that
reimbursement is provided to a healthcare prescriber who provides a non-opioid
treatment to a covered employee under the group insurance plan.
(b) The insurer shall ensure that, to the extent permitted by law, a hospital that
provides either inpatient or outpatient services to a recipient is reimbursed separately
under the group insurance plan for any non-opioid treatment provided as a part of those
services.
SECTION 2. This act takes effect July 1, 2025, the public welfare requiring it.
- 2 - 000599

[DELETED: S5A5(]
[DELETED:  -0((5((S]